Long‐term risk of mortality and loss to follow‐up in children and adolescents on antiretroviral therapy in Asia

Smita Nimkar,Aarti Kinikar,Vidya Mave,Vohith Khol,Quy Tuan Du,Lam Nguyen,Pradthana Ounchanum,Dinh Qui Nguyen,Thanyawee Puthanakit,Pope Kosalaraks,Kulkanya Chokephaibulkit,Tavitiya Sudjaritruk,Dina Muktiarti,Nagalingeswaran Kumarasamy,Nik Khairulddin Nik Yusoff,Thahira Mohamed,Dewi Wati,Anggraini Alam,Siew Fong,Revathy Nallusamy,Tulathip Suwanlerk,Annette Sohn,Azar Kariminia,the TREAT Asia Pediatric HIV Observational Database of IeDEA Asia‐Pacific
DOI: https://doi.org/10.1111/hiv.13718
2024-09-27
HIV Medicine
Abstract:Objective We described mortality and loss to follow‐up (LTFU) in children and adolescents who were under care for more than 5 years following initiation of antiretroviral therapy (ART). Methods Patients were followed from 5 years after ART until the earlier of their 25th birthday, last visit, death, or LTFU. We used Cox regression to assess predictors of mortality and competing risk regression to assess factors associated with LTFU. Results In total, 4488 children and adolescents initiating ART between 1997 and 2016 were included in the analysis, with a median follow‐up time of 5.2 years. Of these, 107 (2.2%) died and 271 (6.0%) were LTFU. Mortality rate was 4.35 and LTFU rate 11.01 per 1000 person‐years. Increased mortality was associated with AIDS diagnosis (adjusted hazard ratio [aHR] 1.71; 95% confidence interval [CI] 1.24–2.37), current CD4 count <350 cells/mm3 compared with ≥500 (highest aHR 13.85; 95% CI 6.91–27.76 for CD4 <200), viral load ≥10 000 copies/mL compared with 1000 copies/mL compared with <400 (highest asHR 2.36; 95% CI 1.19–4.70 for viral load 1000–9999), and ART start after year 2005 compared with ≤2005 (highest asHR 5.96; 95% CI 1.98–17.91 for 2010–2016). Conclusion For children and adolescents surviving 5 years on ART, both current CD4 and viral load remained strong indicators that help to keep track of their treatment outcomes. More effort should be made to monitor patients who switch treatments.
infectious diseases
What problem does this paper attempt to address?